G1 Therapeutics, Inc. – NASDAQ:GTHX
G1 Therapeutics stock price today
$7.14
+3.94
+123.82%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
G1 Therapeutics stock price monthly change
+10.76%
month
G1 Therapeutics stock price quarterly change
-30.04%
quarter
G1 Therapeutics stock price yearly change
+17.71%
year
G1 Therapeutics key metrics
Market Cap | 377.74M |
Enterprise value | 101.29M |
P/E | -0.76 |
EV/Sales | 1.97 |
EV/EBITDA | -0.75 |
Price/Sales | 2.18 |
Price/Book | 1.63 |
PEG ratio | -0.16 |
EPS | -0.59 |
Revenue | 84.04M |
EBITDA | -21.24M |
Income | -30.59M |
Revenue Q/Q | 11.81% |
Revenue Y/Y | 46.55% |
Profit margin | -287.63% |
Oper. margin | -265.45% |
Gross margin | 92.69% |
EBIT margin | -265.45% |
EBITDA margin | -25.28% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeG1 Therapeutics stock price history
G1 Therapeutics stock forecast
G1 Therapeutics financial statements
| Jun 2023 | 42.39M | 8.71M | 20.55% |
|---|---|---|---|
| Sep 2023 | 12.3M | -18.20M | -148% |
| Dec 2023 | 14.87M | -10.87M | -73.14% |
| Mar 2024 | 14.47M | -10.21M | -70.59% |
| Sep 2025 | 27.51M | -2.33M | -8.48% |
|---|---|---|---|
| Oct 2025 | 22.47M | -260.85K | -1.16% |
| Dec 2025 | 23.91M | 782.57K | 3.27% |
| Mar 2026 | 17.65M | -1.61M | -9.13% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 147891000 | 90.34M | 61.09% |
|---|---|---|---|
| Sep 2023 | 133097000 | 90.07M | 67.68% |
| Dec 2023 | 121540000 | 86.15M | 70.89% |
| Mar 2024 | 102026000 | 74.28M | 72.81% |
| Jun 2023 | 14.08M | 346K | -26.75M |
|---|---|---|---|
| Sep 2023 | -10.57M | 7.20M | 22K |
| Dec 2023 | -12.79M | -7.64M | 34K |
| Mar 2024 | -8.89M | 5.28M | -8.72M |
G1 Therapeutics alternative data
| Aug 2023 | 170 |
|---|---|
| Sep 2023 | 170 |
| Oct 2023 | 170 |
| Nov 2023 | 170 |
| Dec 2023 | 170 |
| Jan 2024 | 170 |
| Feb 2024 | 170 |
| Mar 2024 | 100 |
| Apr 2024 | 100 |
| May 2024 | 100 |
| Jun 2024 | 100 |
| Jul 2024 | 100 |
G1 Therapeutics other data
56.68%
-5.74%
of GTHX is owned by hedge funds
110
+3
24.11M
-2.34M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jul 2023 | 0 | 5796 |
| Aug 2023 | 0 | 60000 |
| Dec 2023 | 0 | 33839 |
| Jan 2024 | 0 | 59386 |
| Feb 2024 | 0 | 28600 |
| Mar 2024 | 0 | 6547 |
| May 2024 | 0 | 83839 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | THOMAS MONICA R. officer: Chief Legal & People O.. | Common Stock | 5,826 | $4.27 | $24,865 | ||
Sale | PERRY ANDREW officer: Chief Commercial Officer | Common Stock | 8,151 | $4.79 | $39,035 | ||
Sale | UMSTEAD JOHN W. V officer: Chief Financial Officer | Common Stock | 8,151 | $4.79 | $39,035 | ||
Sale | MURDOCK TERRY L officer: Chief Operating Officer | Common Stock | 8,151 | $4.79 | $39,035 | ||
Sale | MALIK RAJESH officer: Chief Me.. | Common Stock | 8,151 | $4.79 | $39,035 | ||
Sale | AVAGLIANO MARK officer: Chief Bu.. | Common Stock | 8,151 | $4.79 | $39,035 | ||
Sale | BAILEY JOHN E. (JACK) JR. director, officer.. | Common Stock | 37,258 | $4.79 | $178,429 | ||
Sale | UMSTEAD JOHN W. V officer: Chief Financial Officer | Common Stock | 6,547 | $3.02 | $19,752 | ||
Option | MALIK RAJESH officer: Chief Me.. | Common Stock | 28,600 | $0.3 | $8,580 | ||
Sale | MALIK RAJESH officer: Chief Me.. | Common Stock | 28,600 | $4.62 | $132,132 |
| Patent |
|---|
Grant Utility: Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors Filling date: 22 Jan 2019 Issue date: 20 Sep 2022 |
Application Filling date: 11 Apr 2022 Issue date: 4 Aug 2022 |
Grant Filling date: 21 Aug 2019 Issue date: 26 Jul 2022 |
Grant Filling date: 2 Jul 2019 Issue date: 21 Jun 2022 |
Grant Utility: G1T38 superior dosage regimes Filling date: 8 Jul 2020 Issue date: 14 Jun 2022 |
Application Filling date: 17 Dec 2021 Issue date: 9 Jun 2022 |
Application TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS Filling date: 16 Aug 2021 Issue date: 9 Jun 2022 |
Grant Filling date: 19 Dec 2019 Issue date: 1 Mar 2022 |
Application Filling date: 20 Jan 2021 Issue date: 23 Dec 2021 |
Application Filling date: 21 Apr 2021 Issue date: 16 Dec 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Mark A. Velleca M.D., Ph.D. (1964) Senior Advisor & Director | $921,860 |
| Mr. Mark Avagliano (1976) Chief Bus. Officer | $601,060 |
| Dr. Rajesh K. Malik (1959) Chief Medical Officer and Senior Vice President of R&D | $581,300 |
Ms. Jennifer K. Moses CPA (1975) Chief Financial Officer | $548,180 |
| Mr. John E. Bailey Jr. (1965) Chief Executive Officer, Pres & Director | $215,950 |
G1 Therapeutics: New Financials And Big Data Readout Alert
G1 Therapeutics: Flying Low, Too Low
G1 Therapeutics: Without Cash, The CRC Failure Becomes A Tougher Hurdle
G1 Therapeutics: Unexpected Setbacks Yet Value Remains
G1 Therapeutics: Poised For A Turnaround
MDA Breakout Stocks Week 43 - October 2022: Short-Term Picks To Give You An Edge
G1 Therapeutics: Catalysts Stacking
MDA Breakout Stocks Week 42 - October 2022: Short-Term Picks To Give You An Edge
MDA Breakout Stocks Week 40 - October 2022: Short-Term Picks To Give You An Edge
-
What's the price of G1 Therapeutics stock today?
One share of G1 Therapeutics stock can currently be purchased for approximately $7.14.
-
When is G1 Therapeutics's next earnings date?
Unfortunately, G1 Therapeutics's (GTHX) next earnings date is currently unknown.
-
Does G1 Therapeutics pay dividends?
No, G1 Therapeutics does not pay dividends.
-
How much money does G1 Therapeutics make?
G1 Therapeutics has a market capitalization of 377.74M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 60.84% to 82.51M US dollars.
-
What is G1 Therapeutics's stock symbol?
G1 Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "GTHX".
-
What is G1 Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of G1 Therapeutics?
Shares of G1 Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are G1 Therapeutics's key executives?
G1 Therapeutics's management team includes the following people:
- Dr. Mark A. Velleca M.D., Ph.D. Senior Advisor & Director(age: 61, pay: $921,860)
- Mr. Mark Avagliano Chief Bus. Officer(age: 49, pay: $601,060)
- Dr. Rajesh K. Malik Chief Medical Officer and Senior Vice President of R&D(age: 66, pay: $581,300)
- Ms. Jennifer K. Moses CPA Chief Financial Officer(age: 50, pay: $548,180)
- Mr. John E. Bailey Jr. Chief Executive Officer, Pres & Director(age: 60, pay: $215,950)
-
How many employees does G1 Therapeutics have?
As Jul 2024, G1 Therapeutics employs 100 workers.
-
When G1 Therapeutics went public?
G1 Therapeutics, Inc. is publicly traded company for more then 8 years since IPO on 17 May 2017.
-
What is G1 Therapeutics's official website?
The official website for G1 Therapeutics is g1therapeutics.com.
-
Where are G1 Therapeutics's headquarters?
G1 Therapeutics is headquartered at 700 Park Offices Drive, Research Triangle Park, NC.
-
How can i contact G1 Therapeutics?
G1 Therapeutics's mailing address is 700 Park Offices Drive, Research Triangle Park, NC and company can be reached via phone at +91 92139835.
G1 Therapeutics company profile:
G1 Therapeutics, Inc.
g1therapeutics.comExchange:
NASDAQ
Full time employees:
100
Industry:
Biotechnology
Sector:
Healthcare
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
700 Park Offices Drive
Research Triangle Park, NC 27709
Research Triangle Park, NC 27709
CIK: 0001560241
ISIN: US3621LQ1099
CUSIP: 3621LQ109
